You have the opportunity to EXTINGUISH VOD WITH RENAL OR PULMONARY DYSFUNCTION POST HSCT Reach for Defitelio, the first and only approved treatment VOD=veno-occlusive disease Learn more at defitelio.com Indication Defitelio® (defibrotide sodium) is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT). IMPORTANT SAFETY INFORMATION Contraindications Defitelio is contraindicated in the following conditions: Concomitant administration with systemic anticoagulant or fibrinolytic therapy Known hypersensitivity to Defitelio or to any of its excipients ©2018 Jazz Pharmaceuticals DEF-0103b Rev0418http://www.defitelio.com